Results 51 to 60 of about 4,367 (184)

Update on risankizumab for the treatment of moderate to severe psoriasis

, 2020
Introduction: The therapeutic landscape for psoriasis is ever-changing. Risankizumab is the newest approved biologic and one of three currently licensed that targets the p19 subunit of interleukin-23 (IL-23).
Al-Janabi, A; id_orcid, Warren, RB
core   +1 more source

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

Journal of Dermatological Treatment
In the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA).
Joseph F. Merola, April Armstrong, Saakshi Khattri, So Yeon Paek, Byron Padilla, Cuiyong Yue, Huzefa Photowala, Blair Kaplan, Lars Erik Kristensen   +8 more
doaj   +1 more source

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience

Clinical, Cosmetic and Investigational Dermatology, 2023
Melis Gönülal,1 Didem Didar Balcı,1 Serap Öztürkcan2 1Department of Dermatology, University of Health Sciences, Izmir Tepecik Training and Research Hospital, İzmir, Turkey; 2Department of Dermatology, Manisa Celal Bayar University Hafsa ...
Gönülal M, Balcı DD, Öztürkcan S
doaj  

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Risankizumab versus ustekinumab for plaque psoriasis:a critical appraisal [PDF]

, 2019
Aim: Gordon et al investigated the efficacy and safety of risankizumab (an anti-interleukin[IL]23p19 biologic) compared with ustekinumab (anti-IL12/23p40) and placebo in patients with moderate-to-severe chronic plaque psoriasis.
Al-Janabi, A., Yiu, Z. Z. N., Yiu, Zenas; id_orcid, Al-Janabi, Ali; id_orcid, Jabbar-Lopez, Z. K., Jabbar-Lopez, Zarif, Griffiths, C. E. M.   +6 more
core   +1 more source

Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn’s Disease

Gastro Hep Advances
Background and Aims: In phase 3 induction (ADVANCE and MOTIVATE) and maintenance (FORTIFY) trials, risankizumab was shown to benefit symptom and endoscopic defined outcomes in patients with Crohn’s disease (CD). We examined the effects of risankizumab on
Brian G. Feagan, Remo Panaccione, Stefan Schreiber, Edward V. Loftus, Jr., Laurent Peyrin-Biroulet, Takehiro Arai, Wan-Ju Lee, Jenny Griffith, Jasmina Kalabic, Kristina Kligys, Si Xuan, Xiaomei Liao, Marc Ferrante   +12 more
doaj   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months

Dermatology and Therapy
Introduction Risankizumab is approved for treating moderate-to-severe psoriasis. This interim analysis at 25 months evaluated the effectiveness of risankizumab compared with other approved biologics (OtherBios) among patients with moderate-to-severe ...
Diamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, Andrea Szegedi, Paula C. Luna, Charles W. Lynde, Ahmed M. Soliman, Hongwei Wang, Christian Kaufmann, Doug G. Ashley, Tshepiso Madihlaba, Simone Rubant, Kim A. Papp   +12 more
doaj   +1 more source

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States

Journal of Dermatological Treatment, 2023
Aim To compare real-world dose escalation of risankizumab with other US Food and Drug Administration (FDA)-approved biologic treatments for management of moderate-to-severe psoriasis (PsO) in the United States.
Jashin J. Wu, Manish Patel, Feng Zeng, Ahong Huang, Xing Pan, Yiwen Cao, Naijun Chen, Huzefa Photowala, Vishvas Garg, Jeff Crowley   +9 more
doaj   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

International Journal of Dermatology, EarlyView.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer, Martin Valentin Vitus, Tilo Biedermann, Susanne Bauer, Michael Spindler, Mark Berneburg, Dennis Niebel   +15 more
wiley   +1 more source